CRDL Company Profile and Key Details

CRDL has shown mixed momentum, gaining 5.21% over the past week and -1.94% over the past quarter, though year-to-date performance is up 5.89%. Short-term trend indicators are mixed aligned (SMA20 5.28%, SMA50 6.29%, SMA200 -5.61%). The stock’s 14-day RSI is 58.47 (neutral), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.7% below its high and over 38.8% above its low. Average 10-day trading volume of 302.51 thousand shares is below the 3-month average of 662.50 thousand, indicating normal recent market interest.

Cardiol Therapeutics Inc. has 83.73 million shares outstanding. The public float is 80.68 million shares, elevated short interest at 2.31% of float. This equals 1.87 million shares. The short ratio is 1.74 days. Institutional investors hold 8.92% of the float. Insiders own 4.29%.

Cardiol Therapeutics Inc. generated EPS of -$0.30 over the past year. Five-year average earnings growth is 1.3%. Wall Street analysts project EPS growth of 21.9% annually over the next five years. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at -$0.08. Next year's EPS is expected at $13.65. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $8.00. The high target offers 749.06% upside. The low target suggests 654.72% downside. The mean target is $8.67. This offers 717.92% upside. Cardiol Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 0.0%. The prior quarter beat by -44.44%. Over the last six quarters, Apple has recorded several small beats. These include -23.08% in May 13, 2025.

Cardiol Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.17. This means the shares are trading above this model’s fair value.

The stock is currently mid-range between its 52-week high and low $0.88 and $1.71. With a market capitalization of about $122.19 million, Cardiol Therapeutics Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 669.80 thousand shares, volume is running light vs its 52-week average. Headquartered in Oakville, ON, Cardiol Therapeutics Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO David G. Elsley, the company employs approximately 18 people and listed since January 15, 2019. Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD).

Cardiol Therapeutics Inc. (NASDAQ:CRDL) shares are flat 5.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cardiol Therapeutics Inc. trading at a premium to the broader market with a P/E of -3.83. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.31, suggesting 683.96% upside. Our AI forecast model points to short-term weakness (-14.15% over two weeks), a medium-term fall (-36.79% over three months), and a longer-term gain (479.25% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cardiol Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.15%, with price expected at $0.91 by July 06, 2026, within a range of $0.87 to $0.95 3-Month Outlook: Projected fall of -36.79%, reaching $0.67 by September 16, 2026, with a range of $0.57 to $0.74. 1-Year Outlook: Projected gain of 479.25%, with price at $6.14 by June 22, 2027, within a range of $1.61 to $7.58.

Cardiol Therapeutics Inc. trades at a P/E ratio of -3.83, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.74 trading at moderately above to book value. The P/FCF stands at -7.12, also above market averages.